Further information

2019 was a ground breaking year for cannabinoid derived pharmaceuticals in Europe, with growing interest in European research into their therapeutic potential. December 2019 saw the successful fast-track approval of a cannabinoid-based epilepsy drug into the UK's NHS.

This focused conference will put you in front of the research teams exploring the future of therapeutic cannabinoids in a host of disease areas for patients with unmet clinical needs. The comprehensive agenda will address the end to end development challenges which are holding back clinical and commercial success, and give you the insight from world-leading experts to overcome the most critical hurdles.

With 20+ hours of content, interactive workshops and 5 hours+ of networking with your fellow drug developers, this is the only European conference solely focused on the application of cannabinoids for pharmaceutical use in a range of disease indications.